REGENXBIO Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
1,119.00
1,121.00
114,141.00
89,554.00
160,778.00
319,761
Total Accounts Receivable
1,088.00
1,882.00
2,136.00
1,032.00
473.00
8,587
Other Current Assets
-
28.00
1,871.00
2,785.00
6,746.00
9,565
Total Current Assets
2,207.00
3,031.00
118,148.00
93,371.00
167,997.00
337,913
Net Property, Plant & Equipment
-
-
538.00
9,324.00
13,977.00
28,702
Total Investments and Advances
303.00
303.00
102,526.00
69,637.00
16,241.00
152,272
Other Assets
-
157.00
168.00
400.00
462.00
1,915
Total Assets
2,510.00
3,491.00
221,380.00
172,732.00
198,677.00
543,814
ST Debt & Current Portion LT Debt
655.00
3,826.00
-
-
-
Accounts Payable
301.00
334.00
1,014.00
1,543.00
4,832.00
Other Current Liabilities
3,697.00
5,029.00
3,325.00
8,126.00
9,605.00
Total Current Liabilities
4,653.00
9,189.00
4,339.00
9,669.00
14,437.00
Other Liabilities
-
-
233.00
1,326.00
1,211.00
Total Liabilities
4,653.00
9,189.00
4,572.00
10,995.00
15,648.00
Common Equity (Total)
13,921.00
18,291.00
216,808.00
161,737.00
183,029.00
Total Shareholders' Equity
2,143.00
5,698.00
216,808.00
161,737.00
183,029.00
Total Equity
2,143.00
5,698.00
216,808.00
161,737.00
183,029.00
Liabilities & Shareholders' Equity
2,510.00
3,491.00
221,380.00
172,732.00
198,677.00
Preferred Stock (Carrying Value)
11,778.00
12,593.00
-
-
-

About REGENXBIO

View Profile
Address
9600 Blackwell Road
Rockville Maryland 20850
United States
Employees -
Website http://www.regenxbio.com
Updated 07/08/2019
REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M.